Investigational drug · Phase 2
FG001
Also called: Optical imaging agent FG001, Fluorescent imaging agent FG001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for High-Grade Glioma (WHO III-IV).
Phase 2Last checked: Nov 19, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "FG001"
First trial start
2026
Jun 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FG001", any sponsor or status.
Conditions studied
As listed on its trial records.
- High-Grade Glioma (WHO III-IV)
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FG001" as an intervention, largest first.
- FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade GliomaNot yet recruiting
FluoGuide A/SIndustry
NCT07609472 · 76 participants (planned) · Start Jun 30, 2026 · Primary completion Jul 31, 2028
Drug: FG001 · For: High-Grade Glioma (WHO III-IV)
Sites: Miami, Florida; Lebanon, New Hampshire; Pittsburgh, Pennsylvania · 5 sites in all
- FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for NeurosurgeryStatus unknown
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT06684795 · 40 participants (planned) · Start May 1, 2024 · Primary completion Jun 1, 2026
Drug: FG001 prior to surgery · For: Low-grade Glioma; Meningioma; Glioma
Sites: Copenhagen, Denmark
Newest research
PubMed records naming it or its code names, newest first.
- Novel Urokinase-Type Plasminogen Activator Receptor-Targeting Optical Imaging Agent ICG-Glu-Glu-AE105 for Visualization of Malignant Glioma During Surgery: First-in-Human Study in 35 Patients with Brain Cancer.
Skjøth-Rasmussen J, Azam A, Juhl K, et al. · Neurosurgery 2025
- Optical molecular imaging in oral- and oropharyngeal squamous cell carcinoma using a novel uPAR-targeting near-infrared imaging agent FG001 (ICG-Glu-Glu-AE105): An explorative phase II clinical trial.
Andersen AO, Christensen A, Straede K, et al. · Theranostics 2025
- A new uPAR-targeting fluorescent probe for optical guided intracranial surgery in resection of a meningioma-a case report.
Skjøth-Rasmussen J, Azam A, Larsen CC, et al. · Acta Neurochir (Wien) 2022
- The Pathogenesis-Related Maize Seed (PRms) Gene Plays a Role in Resistance to Aspergillus flavus Infection and Aflatoxin Contamination.
Majumdar R, Rajasekaran K, Sickler C, et al. · Front Plant Sci 2017
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.